A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma

Authors

Russell Kent Pachynski, Washington University School of Medicine, St. Louis, MO
Gurkamal S. Chatta, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Rohit K. Jain, H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, FL
Helen H. Moon, Kaiser-SCPMG, Riverside, CA
Randy F. Sweis, The University of Chicago
Scott Delacroix, LSU Health Sciences Center - New OrleansFollow
Alana Fang, Cytel Inc., Seattle, WA
Leonard A. D'amico, Fred Hutchinson Cancer Research Center, Seattle, WA
Angela Shaulov Kask, Fred Hutchinson Cancer Research Center, Seattle, WA
Steven P. Fling, Fred Hutchinson Cancer Research Center, Seattle, WA
Andreanne Lacroix, Fred Hutchinson Cancer Research Center, Seattle, WA
Judith Kaiser, Fred Hutchinson Cancer Research Center, Seattle, WA
Elad Sharon, National Cancer Institute, Bethesda, MD
Evan Y. Yu, Fred Hutchinson Cancer Research Center, Seattle, WA

Document Type

Conference Proceeding

Publication Date

1-29-2024

Publication Title

Journal of Clinical Oncology

Abstract

2024 ASCO Genitourinary Cancers Symposium, January 25 - 27, 2024, San Francisco, CA

Volume

42

Issue

4 Supplement

Recommended Citation

Pachynski, Russell Kent; Chatta, Gurkamal S.; Jain, Rohit K.; Moon, Helen H.; Sweis, Randy F.; Delacroix, Scott; Fang, Alana; D'amico, Leonard A.; Shaulov Kask, Angela; Fling, Steven P.; Lacroix, Andreanne; Kaiser, Judith; Sharon, Elad; and Yu, Evan Y., "A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma" (2024). School of Medicine Faculty Publications. 2385.
https://digitalscholar.lsuhsc.edu/som_facpubs/2385